Researchers from Georgia State University have announced promising results that may place us one step closer to a universal flu vaccine. In a paper published today by Nature Communications, the group led by scientist Bao-Zhon Wang reports the generation of double-layered protein nanoparticles that induced long-lasting immunity to influenza A viruses in mice. [...]Read Full Article →

The discovery of a molecule that blocks the absorption of ghrelin, the also known as the “hunger hormone” due to its effect in regulating hunger, was reported today in Cell Metabolism. The molecule could pave the way for future medications to control hunger and influence the treatment of conditions as diverse as obesity [...]Read Full Article →

Research published today in The Lancet shows evidence of remission of Type 2 Diabetes by intensive weight management in almost 50 percent of cases. Obesity was already considered a risk factor for diabetes, but it is still undetermined whether the effects are reversible. In this study, researchers set to find out whether patients already [...]Read Full Article →

On Nov. 21, the FDA approved the first treatment that uses only two drugs to manage HIV, the virus responsible for AIDS. The new treatment consists of a once-a-day tablet, marketed under the name Juluca, which combines a fixed dose of dolutegravir and rilpivirine. Dolutegravir is an integrase strand transfer inhibitor, first approved by the [...]Read Full Article →

On Monday, Nov. 13, the FDA approved Abilify MyCite, a revolutionary pill that is expected to go a long way to improving adherence issues for medication. The pill consists of a small Proteus microchip covered by aripiprazole, a drug used for the treatment of schizophrenia, bipolar disorder and as a complement for major depressive disorder. [...]Read Full Article →

Revolutionary advances in cancer detection and treatment were discussed by panelists at the Milenio Forum on cancer last week, where the talk centered around the technologies being developed for detection and treatment of the disease, stressing that they should be used intelligently. New techniques discussed included searching for proteins in blood, analyzing spit, and [...]Read Full Article →

Interview with Cristóbal Thompson, Executive Director of AMIIF Q: What are AMIIF’s main priorities for 2016? A: Our primary priority has always been to ensure effective access to pharmaceutical innovation and we are doing this through an extensive approval rate with public institutions, mainly IMSS, ISSSTE, and Seguro Popular. Currently, only 10% of innovative medicines are [...]Read Full Article →

New drug approval is the process through which regulatory agencies authorize a new medicine for commercialization in a specific jurisdiction after thoroughly reviewing the quality, safety, and efficacy of the drug. The number of new molecules approved in a country is a powerful indicator of the degree of access to innovation in healthcare. In 2010, [...]Read Full Article →